Peptides / Longevity and mitochondria

Small molecule · 258.2 Da

AICAR (acadesine)

Not approvedBanned in sport

AICAR, also called acadesine, is a compound that activates the energy enzyme AMPK, not approved and banned in sport. Trials in people tested it in heart surgery and leukemia, but most results come from animal and lab studies. PepBank shows 50 results on AICAR from 8 studies in people, and 1,392 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as AICAR, AICA riboside, AICA-riboside, Arasine, Acadesine

Small molecule, shown without its saltPubChem 17513

Evidence level: Some studies in people50 of 1,442 results come from studies in people.

Results in people

3% of 1,442 results

Results in animals

874

61% of 1,442 results

Results in lab cells

518

36% of 1,442 results

From computer models

0% of 1,442 results

Overview

AICAR (acadesine) at a glance

What it is	Small molecule
Approval	Not approved for any use
In sport	Banned in sport (WADA S4.4.1)
Studies	330 studies with results. 274 of them gave AICAR, with 1,442 results. 50 in people874 in animals518 in lab cells
Best study in people	Randomized controlled trial with 3,080 people (2012)
Clinical trials	3 registered: 0 active or planned, 1 with posted results
Community use	Endurance and exercise-mimetic effects

The science

What is AICAR?

A purine nucleoside analogue that activates AMPK, also called acadesine. It was tested in heart surgery and leukemia trials.

1,442

Study results in PepBank

The history of AICAR

1989
The oldest paper on AICAR in PepBank is from 1989.
2007December
A registered trial of AICAR started (NCT00559624).

AICAR (acadesine) structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Structure

AICAR (acadesine) is a small molecule, not a peptide chain.

Formula

C₉H₁₄N₄O₅

Molecular weight

258.2 g/mol

CAS number

2627-69-2

Target

AMP-activated protein kinase: indirect activator via intracellular ZMPEvidence: curated database or regulator description

Development

PeriCor and Schering-Plough cardiac program. Highest phase: phase 3.

Identifiers

PubChem 17513, ChEMBL CHEMBL1551724, UNII 53IEF47846, DrugBank DB04944

SMILES and InChIKey

InChIKey
RTRQQBHATOEIAF-UUOKFMHZSA-N

SMILES
C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N)C(=O)N

See charge, composition and 3D structure on the Scientific page

The evidence

What AICAR studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Some studies in people50 of 1,442 results come from studies in people.

Heart and blood vessels

117 results · 25 in people · 65 animal · 27 lab

In coronary bypass patients, low-dose acadesine and placebo showed similar ECG signs of reduced heart blood flow before bypass. Anesthesia and analgesia, 1994

Top results

In coronary bypass patients, low-dose acadesine and placebo showed similar ECG signs of reduced heart blood flow before bypass. (Anesthesia and analgesia, 1994)
In CABG patients, acadesine did not reduce the primary composite of death, stroke or support for severe heart dysfunction versus placebo. (JAMA, 2012)
In healthy people, AICA-riboside increased forearm blood flow compared with baseline, with larger responses at higher doses. (American journal of physiology. Endocrinology and metabolism, 2009)

Blood sugar

98 results · 5 in people · 70 animal · 23 lab

In men with diabetes, AICAR reduced glucose appearance compared with control. Diabetologia, 2008

Top results

In men with diabetes, AICAR reduced glucose appearance compared with control. (Diabetologia, 2008)
In rats, AICAR increased insulin-stimulated sugar uptake in epitrochlearis muscle. (Diabetes, 2001)
In rats, AICAR improved heart glucose uptake compared with bypass without AICAR pretreatment. (Cardiovascular therapeutics, 2018)

Cholesterol and blood fats

71 results · 3 in people · 31 animal · 37 lab

In men with diabetes, AICAR reduced fatty acid appearance compared with control. Diabetologia, 2008

Top results

In men with diabetes, AICAR reduced fatty acid appearance compared with control. (Diabetologia, 2008)
In rats with fatty liver disease, AICAR lowered blood triglycerides. (Bioscience reports, 2018)
In mice fed a high-fat diet, AICAR reduced free arachidonic acid in the kidneys. (Journal of lipid research, 2019)

Survival and serious illness

7 results · 2 in people · 5 animal

In coronary bypass patients, overall death rates were similar with acadesine and placebo. The Journal of thoracic and cardiovascular surgery, 1995

Top results

In coronary bypass patients, overall death rates were similar with acadesine and placebo. (The Journal of thoracic and cardiovascular surgery, 1995)
In mice given a Western diet, AICAR improved survival after extensive liver surgery. (Annals of surgery, 2020)
In mice with diet-induced metabolic disease, AICAR improved internal organ pathology. (International journal of molecular sciences, 2022)

Cancer

10 results · 2 in people · 1 animal · 7 lab

In patients with CLL, acadesine showed a trend toward fewer circulating leukemia cells, but results varied. Cancer chemotherapy and pharmacology, 2013

Top results

In patients with CLL, acadesine showed a trend toward fewer circulating leukemia cells, but results varied. (Cancer chemotherapy and pharmacology, 2013)
In cells from human pituitary tumors, four of 15 tumors showed a cell viability response to AICAR. (Molecular and cellular endocrinology, 2013)
In patients with CLL, acadesine showed a trend toward smaller enlarged lymph nodes, but results varied. (Cancer chemotherapy and pharmacology, 2013)

Metabolism and nutrition

8 results · 1 in people · 7 animal

In patients undergoing coronary angiography, acadesine increased blood lactate compared with placebo. European journal of pharmacology, 1997

Top results

In patients undergoing coronary angiography, acadesine increased blood lactate compared with placebo. (European journal of pharmacology, 1997)
In mice exposed to fine particulate matter, AICAR increased energy metabolism. (Ecotoxicology and environmental safety, 2019)
In rats studied alongside cells with kidney injury, AICAR restored multiple metabolites associated with several metabolic pathways. (Cellular and molecular life sciences, 2026)

All 330 AICAR studies by area Open the Scientific page

Key AICAR studies

Studies in people come first, then studies in animals and in the lab.

People
Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial
Newman et al. 2012 · JAMA · 3,080 people · cited by 43
2 results
People
Acadesine: a new drug that may improve myocardial protection in coronary artery bypass grafting. Results of the first international multicenter study. Multinational Acadesine Study Group
Menasché et al. 1995 · The Journal of thoracic and cardiovascular surgery · 821 people · cited by 27
6 results
People
Effects of acadesine on the incidence of myocardial infarction and adverse cardiac outcomes after coronary artery bypass graft surgery. Multicenter Study of Perioperative Ischemia (McSPI) Research Group
1995 · Anesthesiology · 633 people · cited by 19
10 results
People
An initial multicenter, randomized controlled trial on the safety and efficacy of acadesine in patients undergoing coronary artery bypass graft surgery. SPI Research Group
Leung et al. 1994 · Anesthesia and analgesia · cited by 37
9 results
People
Effect of acadesine on myocardial ischaemia in patients with coronary artery disease
de et al. 1997 · European journal of pharmacology · 47 people · cited by 9
4 results

All 330 AICAR (acadesine) studies

AICAR clinical trials

ClinicalTrials.gov lists 3 trials of AICAR. 0 are active or planned, and 1 has posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633 AM1)(TERMINATED)

Phase 3terminated3,080 planned

Safety and Tolerability Open Label Dose Escalation Study of Acadesine in B-CLL Patients

Phase 1/2completed40 people

GFM-Acadesine: A Phase I-II Trial of Acadesine

Phase 1/2terminated5 planned

Status and safety

Is AICAR approved?

FDA

United States

Not approved

No approved medicine contains it.

EMA

European Union

Not approved

No approved medicine contains it.

WADA

Sport

Banned

On the 2026 Prohibited List, section S4.4.1.

No. Not approved for any use. Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 21 Oct 2026). Banned in sport (WADA S4.4.1).

Laws and labels change, so check the regulator for the current status.

AICAR side effects and safety

PepBank has 19 safety results from studies of AICAR. 12 of them come from studies in people.

Safety results from studies (19)

In coronary bypass patients, overall death rates were similar with acadesine and placebo. (The Journal of thoracic and cardiovascular surgery, 1995)
In coronary bypass patients, adverse event rates were similar with acadesine and placebo, except for higher uric acid at high doses. (Anesthesiology, 1995)
In coronary bypass patients, only high-dose acadesine mildly increased uric acid, without clinical consequences. (Anesthesia and analgesia, 1994)
In patients with previously treated CLL, single acadesine doses between 50 and 210 mg/kg showed a manageable safety profile. (Cancer chemotherapy and pharmacology, 2013)
In coronary bypass patients, acadesine reduced deaths during the first postoperative days compared with placebo. (The Journal of thoracic and cardiovascular surgery, 1995)
In coronary bypass patients, the study linked no adverse events to acadesine treatment. (The Journal of thoracic and cardiovascular surgery, 1995)
In coronary bypass patients, high-dose acadesine temporarily increased blood uric acid compared with placebo. (Anesthesiology, 1995)
In patients with previously treated CLL, acadesine's maximum tolerated and optimal biological dose was 210 mg/kg. (Cancer chemotherapy and pharmacology, 2013)
In patients with CLL receiving acadesine, grade ≥2 high uric acid occurred commonly without clinical significance and resolved with preventive allopurinol. (Cancer chemotherapy and pharmacology, 2013)
In patients with CLL, acadesine adverse events included temporary anemia and/or low platelets without clinical significance. (Cancer chemotherapy and pharmacology, 2013)
In patients with CLL, acadesine adverse events included impaired kidney function. (Cancer chemotherapy and pharmacology, 2013)
In patients with CLL, acadesine adverse events included temporary, clinically significant low blood pressure during infusion. (Cancer chemotherapy and pharmacology, 2013)
In ob/ob mice, AICAR adversely affected blood non-esterified fatty acids compared with vehicle. (Diabetologia, 2002)
In mice, AICAR increased blood triglycerides compared with vehicle. (Biochemical and biophysical research communications, 2002)
In obese mice with pancreatitis, AICAR reduced deaths. (Cell death discovery, 2023)
In mice on a standard diet, AICAR treatment from the first day produced some liver toxicity. (International journal of molecular sciences, 2022)
In baboons born prematurely, one animal developed complications during AICAR treatment. (PloS one, 2018)
In ob/ob mice, AICAR adversely affected blood triglycerides compared with vehicle. (Diabetologia, 2002)
In cells, AICAR treatment produced the highest cell death level among the groups. (Stem cell research & therapy, 2020)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
0.1 mg/kg per minute	Human	human	Not reported	7 hours	Randomized trial in people · n = 2,986	Newman 2012
0.1 mg/kg per minute intravenously and 5 micrograms/ml in cardioplegic solution	Human	human	Intravenous infusion and cardioplegic solution	7 hours	Randomized trial in people	Menasché 1995
0.1 mg.kg-1.min-1 plus 5 micrograms/ml cardioplegia	Human	human	Intravenous infusion and cardioplegic solution	7 h	Randomized trial in people	1995
0.05 or 0.1 mg.kg-1.min-1 plus 5 micrograms/ml cardioplegia	Human	human	Intravenous infusion and cardioplegic solution	7 h	Randomized trial in people · n = 633	1995
5, 10, 20, 50 mg/kg	Human	human	intravenous	Not reported	Trial in people without random groups · n = 47	de 1997
0.75 mg kg(-1) min(-1)	Human	human	intravenous	Not reported	Trial in people without random groups · n = 10	Boon 2008
50-210 mg/kg	Human	human	intravenous 4-h infusion	Not reported	Trial in people without random groups	Van 2013
210 mg/kg	Human	human	intravenous 4-h infusion	Not reported	Trial in people without random groups	Van 2013
four dosages up to 8 mg x min(-1) x dl(-1)	Human	human	intra-arterial	Not reported	Trial in people without random groups	Bosselaar 2009
500 mg/kg	Animal	mouse	intraperitoneal	Not reported	Study in live animals · n = 20	Wang 2026
2.5 mg.kg-1.min-1 for 5 minutes, then 0.5 mg.kg-1.min-1 intravenously; 20 mumol/L in cardioplegia	Animal	dog	Intravenous and cardioplegic solution	Before and during ischemia until 10 minutes after aortic cross-clamp removal	Study in live animals · n = 16	Bolling 1992
0.5 mg/g body wt daily	Animal	rat	subcutaneous	7 weeks	Study in live animals · n = 12	Buhl 2002
2.5 mg/kg over 5 min, then 0.5 mg.kg-1.min-	Animal	cat	intravenous	Before ischemia through 30 min after reperfusion	Study in live animals · n = 12	Schoenberg 1995
0.5 mg·g-1·day-1	Animal	baboon	intravenous infusion	5 days	Study in live animals · n = 11	Blanco 2018
0.5 mg/kg/min	Animal	dog	intravenous	Not reported	Study in live animals · n = 3	Young 1995
bolus 100 mg/kg; constant 10 mg.kg(-1).min(-1)	Animal	rat	infusion	90 min	Study in live animals	Bergeron 2001
0.5 mg g/body weight	Animal	mouse	intraperitoneal	6 weeks	Study in live animals	Giri 2006
1 mg.g body wt(-1).day(-1)	Animal	mouse	subcutaneous	1-7 days	Study in live animals	Song 2002
1 mg/g body wt	Animal	rat	subcutaneous	5 days	Study in live animals	Buhl 2001
500 mg·kg(-1)	Animal	rat	intravenous	Not reported	Study in live animals	Lempiäinen 2012
500 mg/kg	Animal	mouse	injection	3 days	Study in live animals	Kobilo 2014
1 mg/g body wt	Animal	rat	subcutaneous	Not reported	Study in live animals	Thomson 2008
0.5 mg/g body wt	Animal	rat	Not reported	7 weeks	Study in live animals	Li 2007
1.0 g kg(-1)	Animal	mouse	Not reported	Two hours	Study in live animals	Zwetsloot 2008
500 mg·kg(-1)·day(-1)	Animal	mouse	Not reported	30 days	Study in live animals	Ljubicic 2012
500 mg/kg	Animal	mouse	Not reported	7 and 14 days	Study in live animals	Guerrieri 2015
50 mg/kg b.i.d.	Animal	rat	intraperitoneal	days 14-18 of gestation	Study in live animals	Banek 2013
0.5 mg·g body wt(-1)·day(-1)	Animal	mouse	injection	14 days	Study in live animals	Drake 2010
200 mg/kg daily	Animal	mouse	intraperitoneal	day 0 until day 21	Study in live animals	Suzuki 2012
1 mg (g body weight)(-1)	Animal	rat	subcutaneous	1 h	Study in live animals	Thomson 2009
200 mg kg-1 day-1	Animal	mouse	subcutaneous pellet	Not reported	Study in live animals	Lane 2020
500 μg/g three times/week	Animal	mouse	Not reported	weeks 4-12	Study in live animals	Börgeson 2017
125 mg/kg	Animal	mouse	intraperitoneal injection	5 days	Study in live animals	Sano 2014
250 mg/kg	Animal	mouse	intraperitoneal injection	5 days	Study in live animals	Sano 2014
0.5 mg/g/day	Animal	mouse	subcutaneous	4 weeks	Study in live animals	Chen 2017
30 mg/kg BW	Animal	rat	intravenous	30 min	Study in live animals	Idrovo 2015
20 mg/kg/day	Animal	rat	intravenous	3 weeks	Study in live animals	Pavlov 2017
20 ng	Animal	mouse	intracerebroventricular injection	Not reported	Study in live animals	Mulchandani 2015
30 mg/kg BW	Animal	rat	Not reported	Not reported	Study in live animals	Idrovo 2012
0.5 mg/g body weight	Animal	rat	intraperitoneal	10 days	Study in live animals	McConell 2008

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

A guide reports low-confidence AICAR use for endurance and metabolic effects. It labels these doses as community extrapolations.

Reported routines and cautions

What people use it for

Endurance and exercise-mimetic effectsS1

Reported regimens

Regimens that community sources report for AICAR (acadesine). Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Low-confidence community estimate	subcutaneous injection	500 to 2000 mg per dose	daily	30 to 60 days, then long breaks	Single source. The source carries seller advertisements or affiliate links.	S1

Cautions

The source states that subcutaneous community use lacks human trial data. Hospital intravenous trials do not establish safety for this route or repeated healthy-user use.S1

Community sources

S1AICAR guide, StackTraxstacktrax.comcarries seller links, not linked

Gaps

Only one guide supports these amounts. It reports circulating estimates, not verified user treatment records.

Questions and more

Ask a question about AICAR

The answer links to every study it uses.

What does the evidence say about AICAR?Is AICAR tested in people?Compare with NMN (nicotinamide mononucleotide)Compare with Humanin

Sources

Database: PepBank data for AICAR (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about AICAR

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

AICAR (acadesine)

Not approvedBanned in sport

Also known as AICAR, AICA riboside, AICA-riboside, Arasine, Acadesine

What it is

Small molecule

Approval

Not approved for any use

In sport

Banned in sport (WADA S4.4.1)

Studies

330 studies with results. 274 of them gave AICAR, with 1,442 results.
50 in people874 in animals518 in lab cells

Best study in people

Randomized controlled trial with 3,080 people (2012)

Clinical trials

3 registered: 0 active or planned, 1 with posted results

Community use

Endurance and exercise-mimetic effects

Dose as reported

Class

Species

Route

Duration

Design

Source

0.1 mg/kg per minute

Human

human

Not reported

7 hours

Randomized trial in people · n = 2,986

Newman 2012

0.1 mg/kg per minute intravenously and 5 micrograms/ml in cardioplegic solution

Human

human

Intravenous infusion and cardioplegic solution

7 hours

Randomized trial in people

Menasché 1995

0.1 mg.kg-1.min-1 plus 5 micrograms/ml cardioplegia

Human

human

Intravenous infusion and cardioplegic solution

7 h

Randomized trial in people

1995

0.05 or 0.1 mg.kg-1.min-1 plus 5 micrograms/ml cardioplegia

Human

human

Intravenous infusion and cardioplegic solution

7 h

Randomized trial in people · n = 633

1995

5, 10, 20, 50 mg/kg

Human

human

intravenous

Not reported

Trial in people without random groups · n = 47

de 1997

0.75 mg kg(-1) min(-1)

Human

human

intravenous

Not reported

Trial in people without random groups · n = 10

Boon 2008

50-210 mg/kg

Human

human

intravenous 4-h infusion

Not reported

Trial in people without random groups

Van 2013

210 mg/kg

Human

human

intravenous 4-h infusion

Not reported

Trial in people without random groups

Van 2013

four dosages up to 8 mg x min(-1) x dl(-1)

Human

human

intra-arterial

Not reported

Trial in people without random groups

Bosselaar 2009

500 mg/kg

Animal

mouse

intraperitoneal

Not reported

Study in live animals · n = 20

Wang 2026

2.5 mg.kg-1.min-1 for 5 minutes, then 0.5 mg.kg-1.min-1 intravenously; 20 mumol/L in cardioplegia

Animal

dog

Intravenous and cardioplegic solution

Before and during ischemia until 10 minutes after aortic cross-clamp removal

Study in live animals · n = 16

Bolling 1992

0.5 mg/g body wt daily

Animal

rat

subcutaneous

7 weeks

Study in live animals · n = 12

Buhl 2002

2.5 mg/kg over 5 min, then 0.5 mg.kg-1.min-

Animal

cat

intravenous

Before ischemia through 30 min after reperfusion

Study in live animals · n = 12

Schoenberg 1995

0.5 mg·g-1·day-1

Animal

baboon

intravenous infusion

5 days

Study in live animals · n = 11

Blanco 2018

0.5 mg/kg/min

Animal

dog

intravenous

Not reported

Study in live animals · n = 3

Young 1995

bolus 100 mg/kg; constant 10 mg.kg(-1).min(-1)

Animal

rat

infusion

90 min

Study in live animals

Bergeron 2001

0.5 mg g/body weight

Animal

mouse

intraperitoneal

6 weeks

Study in live animals

Giri 2006

1 mg.g body wt(-1).day(-1)

Animal

mouse

subcutaneous

1-7 days

Study in live animals

Song 2002

1 mg/g body wt

Animal

rat

subcutaneous

5 days

Study in live animals

Buhl 2001

500 mg·kg(-1)

Animal

rat

intravenous

Not reported

Study in live animals

Lempiäinen 2012

500 mg/kg

Animal

mouse

injection

3 days

Study in live animals

Kobilo 2014

1 mg/g body wt

Animal

rat

subcutaneous

Not reported

Study in live animals

Thomson 2008

0.5 mg/g body wt

Animal

rat

Not reported

7 weeks

Study in live animals

Li 2007

1.0 g kg(-1)

Animal

mouse

Not reported

Two hours

Study in live animals

Zwetsloot 2008

500 mg·kg(-1)·day(-1)

Animal

mouse

Not reported

30 days

Study in live animals

Ljubicic 2012

500 mg/kg

Animal

mouse

Not reported

7 and 14 days

Study in live animals

Guerrieri 2015

50 mg/kg b.i.d.

Animal

rat

intraperitoneal

days 14-18 of gestation

Study in live animals

Banek 2013

0.5 mg·g body wt(-1)·day(-1)

Animal

mouse

injection

14 days

Study in live animals

Drake 2010

200 mg/kg daily

Animal

mouse

intraperitoneal

day 0 until day 21

Study in live animals

Suzuki 2012

1 mg (g body weight)(-1)

Animal

rat

subcutaneous

1 h

Study in live animals

Thomson 2009

200 mg kg-1 day-1

Animal

mouse

subcutaneous pellet

Not reported

Study in live animals

Lane 2020

500 μg/g three times/week

Animal

mouse

Not reported

weeks 4-12

Study in live animals

Börgeson 2017

125 mg/kg

Animal

mouse

intraperitoneal injection

5 days

Study in live animals

Sano 2014

250 mg/kg

Animal

mouse

intraperitoneal injection

5 days

Study in live animals

Sano 2014

0.5 mg/g/day

Animal

mouse

subcutaneous

4 weeks

Study in live animals

Chen 2017

30 mg/kg BW

Animal

rat

intravenous

30 min

Study in live animals

Idrovo 2015

20 mg/kg/day

Animal

rat

intravenous

3 weeks

Study in live animals

Pavlov 2017

20 ng

Animal

mouse

intracerebroventricular injection

Not reported

Study in live animals

Mulchandani 2015

30 mg/kg BW

Animal

rat

Not reported

Study in live animals

Idrovo 2012

0.5 mg/g body weight

Animal

rat

intraperitoneal

10 days

Study in live animals

McConell 2008

Context

Route

Amount

How often

How long

Agreement

Sources

Low-confidence community estimate

subcutaneous injection

500 to 2000 mg per dose

daily

30 to 60 days, then long breaks

Single source. The source carries seller advertisements or affiliate links.

AICAR (acadesine)

AICAR (acadesine) at a glance

What is AICAR?

The history of AICAR

AICAR (acadesine) structure and chemistry

What AICAR studies show

Heart and blood vessels

Blood sugar

Cholesterol and blood fats

Survival and serious illness

Cancer

Metabolism and nutrition

Key AICAR studies

AICAR clinical trials

Is AICAR approved?

AICAR side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Community sources

Ask a question about AICAR

Related peptides

Sources

AICAR (acadesine)

AICAR (acadesine) at a glance

What is AICAR?

The history of AICAR

AICAR (acadesine) structure and chemistry

What AICAR studies show

Heart and blood vessels

Blood sugar

Cholesterol and blood fats

Survival and serious illness

Cancer

Metabolism and nutrition

Key AICAR studies

AICAR clinical trials

Is AICAR approved?

AICAR side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Community sources

Ask a question about AICAR

Related peptides

Sources